이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

2026년 11월 4일 업데이트: Gilead Sciences

안정적인 복합 치료 요법에 대한 바이러스 억제 HIV-1 환자를 대상으로 빅테그라비르/레나카파비르 대 안정 기준 요법의 안전성 및 효능을 평가하기 위한 운영상 원활한 2/3상 무작위, 공개 라벨, 다기관, 능동 대조 연구

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

689

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Cape Town, 남아프리카, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, 남아프리카, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, 남아프리카, 2193
        • Ezintsha
      • Kaohsiung City, 대만, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, 대만, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, 대만, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, 대만, 33004
        • Taoyuan General Hospital
      • Daegu, 대한민국, 41944
        • Kyungpook National University Hospital
      • Daejeon, 대한민국, 35015
        • Chungnam National University Hospital
      • Seoul, 대한민국, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, 대한민국, 03722
        • Yonsei University Severance Hospital
      • Santo Domingo, 도미니카 공화국
        • Instituto Dominicano de Estudio Virologicos - IDEV
      • Berlin, 독일, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, 독일, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, 독일, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, 독일, 20146
        • ICH Study Center GmbH & Co. KG
      • München, 독일
        • MVZ München am Goetheplatz
    • California
      • Berkeley, California, 미국, 48072
        • Be Well Medical Center
      • Beverly Hills, California, 미국, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, 미국, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, 미국, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, 미국, 92262
        • Bios Clinical Research
      • San Diego, California, 미국, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, 미국, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, 미국, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, 미국, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, 미국, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, 미국, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, 미국, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, 미국, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, 미국, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, 미국, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, 미국, 33016
        • Floridian Clinical Research
      • Orlando, Florida, 미국, 32803
        • Orlando Immunology Center
      • Orlando, Florida, 미국, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, 미국, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, 미국, 30309
        • Atlanta ID Group
      • Macon, Georgia, 미국, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, 미국, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, 미국, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, 미국, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, 미국, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, 미국, 11355
        • New York Presbyterian Hospital
      • New York, New York, 미국, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, 미국, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, 미국, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, 미국, 77401
        • St. Hope Foundation
      • Dallas, Texas, 미국, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, 미국, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, 미국, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, 미국, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, 미국, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, 미국, 98104
        • Peter Shalit, MD
      • Barcelona, 스페인, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, 스페인, 28040
        • Hospital Clinico San Carlos
      • Madrid, 스페인, 28046
        • Hospital Universitario La Paz
      • Madrid, 스페인, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, 스페인, 4103
        • Hospital Universitario Virgen del Rocio
      • Buenos Aires, 아르헨티나, 1202
        • Fundación Huésped
      • Buenos Aires, 아르헨티나, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, 아르헨티나, 1425
        • Helios Salud
      • Birmingham, 영국, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, 영국, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, 영국, E1 1BB.
        • Barts Health NHS Trust
      • London, 영국, SE5 9RS
        • HIV medicine and infectious diseases
      • London, 영국, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
      • Milan, 이탈리아, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, 이탈리아, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, 이탈리아, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, 이탈리아, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, 이탈리아, 10149
        • ASL Città di Torino
      • Nagoya, 일본
        • National Hospital Organization Nagoya Medical Center
      • Osaka, 일본, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, 일본, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine
      • Decarie Montreal, 캐나다, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, 캐나다, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, 캐나다, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, 캐나다, S4P 0W5
        • ID Clinic
      • Toronto, 캐나다, M5G 1K2
        • Maple Leaf Research
      • Vancouver, 캐나다, V6Z 2T1
        • Spectrum Health
    • PR
      • San Juan, PR, 푸에르토 리코, 00909
        • Hope Clinical Research
      • San Juan, PR, 푸에르토 리코, 00935
        • Proyecto ACTU
      • Nice, 프랑스, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, 프랑스, 75010
        • Hospital Saint Louis
      • Paris, 프랑스, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, 프랑스, 75651
        • Höpital de la Pitié Salpêtrière
    • New South Wales
      • Darlinghurst, New South Wales, 호주, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, 호주, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, 호주, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, 호주, 3004
        • Alfred Health

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

다른 이름들:
  • GS-6207

Tablets administered orally without regard to food

다른 이름들:
  • GS-9883
실험적: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

다른 이름들:
  • GS-6207

Tablets administered orally without regard to food

다른 이름들:
  • GS-9883
활성 비교기: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
실험적: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

다른 이름들:
  • Bixlenvo™
활성 비교기: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
실험적: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

다른 이름들:
  • GS-6207

Tablets administered orally without regard to food

다른 이름들:
  • Bixlenvo™

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
기간: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

2차 결과 측정

결과 측정
측정값 설명
기간
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
기간: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
기간: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
기간: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
기간: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
기간: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
기간: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
기간: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
기간: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
기간: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
기간: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
기간: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
기간: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
기간: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
기간: Week 144
Week 144

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 8월 16일

기본 완료 (실제)

2025년 9월 29일

연구 완료 (추정된)

2029년 12월 1일

연구 등록 날짜

최초 제출

2022년 8월 5일

QC 기준을 충족하는 최초 제출

2022년 8월 12일

처음 게시됨 (실제)

2022년 8월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • GS-US-621-6289
  • 2022-500929-33 (기타 식별자: European Medicines Agency)
  • DOH-27-052023-8574 (기타 식별자: South African Clinical Trial Registry)
  • jRCT2051230168 (기타 식별자: Japan registry)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .